Brief: ALX Oncology And Quantum Leap Healthcare Collaborative Announce Selection Of Evorpacept In I-Spy-P1 Trial In Combination With Enhertu In Breast Cancer
15/08/2022 12:52
Aug 15 (Reuters) - ALX Oncology Holdings Inc ALXO.O :
* ALX ONCOLOGY AND QUANTUM LEAP HEALTHCARE COLLABORATIVE
ANNOUNCE
SELECTION OF EVORPACEPT IN I-SPY-P1 TRIAL IN COMBINATION WITH
ENHERTU IN BREAST CANCER
* ALX ONCOLOGY - AS STUDY SPONSOR, QUANTUM LEAP WILL BE
RESPONSIBLE FOR MANAGING TRIAL
Source text for Eikon: ID:nGNX2hL840
Further company coverage: ALXO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing